Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (131)	2/5/2002 9:36:14 PM
From: mopgcw	Read Replies (2) \| Respond to of 598

Tularik Announces Departure of Andrew J. Perlman, EVP SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Feb. 5, 2002-- Tularik Inc. (Nasdaq:TLRK - news) today announced that Andrew J. Perlman, M.D., Ph.D. has resigned his position as Executive Vice President in order to join Affymax, Inc., a private drug-discovery company, as Chief Executive Officer. ``Andy is an esteemed colleague and a close personal friend who will be missed by the entire Tularik team,'' said David V. Goeddel, Ph.D., Tularik's CEO. ``Over the past nine years, his contributions have helped Tularik become an integrated drug discovery and development company. Although we are sad to see him go, we understand his decision to pursue this opportunity and we wish him great success.''